{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/opioid-dependence/","result":{"data":{"firstChapter":{"id":"7b9e0e1a-3aea-5219-a001-dfd22a786292","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 112a7db8-368d-4981-8a3a-2708e31cf3b6 --><h1>Opioid dependence: Summary</h1><!-- end field 112a7db8-368d-4981-8a3a-2708e31cf3b6 -->","htmlStringContent":"<!-- begin item 2d4a34e3-2cd5-4f3b-a10c-2ffa34612816 --><!-- begin field 7d0386e2-3e5f-4aa6-a67c-0c228f85f3e4 --><ul><li>An opioid is either a natural derivative of opium or a synthetic substance with agonist, partial agonist, or mixed agonist and antagonist activity at opioid receptors.</li><li>Opioid dependence develops after a period of regular use of opioids, with the time required varying according to the quantity, frequency and route of administration, factors of individual vulnerability and the context in which drug use occurs.<ul><li>Physical and psychological dependence can develop within a relatively short period of continuous use (2–10 days).</li></ul></li><li>The key elements of opioid dependence include a strong desire or sense of compulsion to take opioids; difficulty in controlling use; a physiological withdrawal state when opioid use has ceased or been reduced; evidence of tolerance; progressive neglect of alternative pleasures and interests; and persistence with opioid use despite clear evidence of overtly harmful consequences.</li><li>Complications include overdose which can result in death, infections such as HIV and hepatitis C (especially from using shared injection equipment), and social problems such as homelessness and crime.</li><li>Opioid dependence should be suspected in people who actively ask for help for dependency, and those with:<ul><li>A complication of illicit drug use. </li><li>Clinical features of opioid intoxication, or withdrawal.</li><li>A psychiatric, forensic, or social history which may be related to opioid dependency. </li><li>Signs or symptoms of dependency, such as poor nutrition, needle tracks, or skin abscess.</li></ul></li><li>The need for opioid substitution therapy should be assessed and whether to opt for maintenance therapy or detoxification discussed. If substitution is being considered, opioid use should be confirmed by testing for the presence of opioids in oral fluids or urine.<ul><li>The goal of maintenance therapy is harm reduction and stabilization of lifestyle. </li><li>The goal of detoxification is to come off opioids altogether. </li></ul></li><li>Advice should be offered on immunizations, harm reduction, driving regulations, as well as overdose prevention training and take-home naloxone.</li><li>A report should be made to the National Drug Treatment Monitoring System (NDTMS) when a person first starts treatment for drug misuse (this is anonymous data, but patient consent must be obtained).</li><li>The decision on whether to start on methadone or buprenorphine should be made with the person, and take into account:<ul><li>Their preference for either drug.</li><li>Previous substantial benefit from maintenance on either medicine.</li><li>Specific safety concerns.</li><li>The likely need for strong opioids other than buprenorphine for pain management. </li><li>Any relevant drug-drug interactions.</li></ul></li><li>Supervised consumption should be arranged for the person for at least the first 3 months.</li><li>Ideally, the person should be seen daily for the first few days during initiation to titrate the dose against response. <ul><li>If this is not practicable, the person should be seen every few days.</li></ul></li><li>Regular reviews should be tailored to the individual needs of the person at least fortnightly initially, and then, if stable, at least monthly, or less frequently if very stable. <ul><li>A thorough review should be conducted at least every 3–4 months.</li></ul></li></ul><!-- end field 7d0386e2-3e5f-4aa6-a67c-0c228f85f3e4 --><!-- end item 2d4a34e3-2cd5-4f3b-a10c-2ffa34612816 -->","topic":{"id":"ef534296-f504-5d3e-9b47-3c0f08322658","topicId":"1acd30d9-6aea-492b-a570-5fbeb05d49f5","topicName":"Opioid dependence","slug":"opioid-dependence","aliases":[],"chapters":[{"id":"7b9e0e1a-3aea-5219-a001-dfd22a786292","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"a0179729-bb50-55a3-a1dc-ca3cbd473972","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"e63e1346-068d-56e6-891b-85878800d361","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"37edcefe-2b9f-5ab8-a584-be9e268559ac","slug":"changes","fullItemName":"Changes"},{"id":"b53b49f5-e58d-5325-8fee-7f9fdc057646","slug":"update","fullItemName":"Update"}]},{"id":"242f440f-b9b5-51a4-9d43-3492e963e9af","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"5766349b-04fe-548c-9de5-0ff28c7803b9","slug":"goals","fullItemName":"Goals"},{"id":"2ed8ffe3-15a2-5e49-b2ad-033e1a4b5f22","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"419add6c-5149-5bbf-9be1-8854fefbccc4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01b28023-8c52-53e9-a23d-43bb73f67990","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e459f916-c763-56aa-9a4e-a3e6ef261b0f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a96bc65-6eb3-5a1c-99c3-2530b6d352f4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b1fa8640-11da-554d-9d7a-12696b906136","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"28447573-cc1d-50d6-bea5-720f6d22e335","slug":"definition","fullItemName":"Definition"},{"id":"d7f47150-a2c5-57f9-88aa-5353f86fc58a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e594be8-c4df-5032-ad75-87ab56cb2c7e","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7da5320-e6b9-59fc-8e5a-558ea4c298d9","slug":"complications","fullItemName":"Complications"}]},{"id":"e747d7e1-25ca-5f67-9d22-349d2b18eddd","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"ee9cab5c-4665-56a2-9005-028143cc8f59","slug":"suspecting-opioid-dependency","fullItemName":"Suspecting opioid dependency"},{"id":"20c15a53-634f-5cb4-a88a-7cb5115d810b","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"f37505e6-dc82-5755-b700-7d1966f8c252","slug":"management","fullItemName":"Management","subChapters":[{"id":"75fe82a9-9ba2-541a-80be-cd0cf879bca3","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"d05968e4-f2be-5378-b462-0b129f5dc5e6","slug":"management","fullItemName":"Scenario: Management"},{"id":"00d16467-be2b-538d-8a7c-4d4045cabd6e","slug":"managing-special-circumstances","fullItemName":"Scenario: Managing special circumstances"}]},{"id":"0cf2cc09-9ca4-58a8-91c7-d64c38924b5a","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"ccbe88d0-314a-57fa-a61a-8a83bbfc9baf","slug":"writing-prescriptions-for-substitution-therapy","fullItemName":"Writing prescriptions for substitution therapy"},{"id":"5c859eeb-d8fd-50f5-8b18-e1a6a71ac111","slug":"methadone","fullItemName":"Methadone"},{"id":"3021db45-0a93-5ca8-a386-8d3e71abad63","slug":"buprenorphine","fullItemName":"Buprenorphine"}]},{"id":"9547692f-53b7-5f09-944d-6a4a6229dead","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"0eafd778-db7f-578e-905f-1365ee1290a1","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"1d80b232-8932-503b-8765-30b929f15180","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"796c8942-47b7-56b5-a88a-cc0f133f5f3e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfb530c5-aa05-5f4c-9e26-43caae839601","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"955b9fba-573b-57a0-b099-cf3356d6e837","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f05fac2-c160-5e48-b55d-3898cce03ec0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0ead7d6b-f923-5852-bb7c-50aa97b9b2ff","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"ef534296-f504-5d3e-9b47-3c0f08322658","topicId":"1acd30d9-6aea-492b-a570-5fbeb05d49f5","topicName":"Opioid dependence","slug":"opioid-dependence","aliases":[],"topicSummary":"All opioids have dependence potential to varying degrees. Heroin  has the greatest potential for dependency. It can develop within 210 days of use.","lastRevised":"Last revised in October 2020","nextPlannedReviewBy":"2025-07-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2025-06","nextPlannedReviewByDisplay":"June 2025","specialities":[{"id":"45db1917-4d65-58d8-af3d-568321e486ed","name":"Drugs and devices","slug":"drugs-devices"},{"id":"460cf76a-c057-55d8-a7ab-50fe9463f7da","name":"Mental health","slug":"mental-health"}],"chapters":[{"id":"7b9e0e1a-3aea-5219-a001-dfd22a786292","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"a0179729-bb50-55a3-a1dc-ca3cbd473972","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"e63e1346-068d-56e6-891b-85878800d361","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"37edcefe-2b9f-5ab8-a584-be9e268559ac","slug":"changes","fullItemName":"Changes"},{"id":"b53b49f5-e58d-5325-8fee-7f9fdc057646","slug":"update","fullItemName":"Update"}]},{"id":"242f440f-b9b5-51a4-9d43-3492e963e9af","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"5766349b-04fe-548c-9de5-0ff28c7803b9","slug":"goals","fullItemName":"Goals"},{"id":"2ed8ffe3-15a2-5e49-b2ad-033e1a4b5f22","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"419add6c-5149-5bbf-9be1-8854fefbccc4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01b28023-8c52-53e9-a23d-43bb73f67990","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e459f916-c763-56aa-9a4e-a3e6ef261b0f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a96bc65-6eb3-5a1c-99c3-2530b6d352f4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b1fa8640-11da-554d-9d7a-12696b906136","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"28447573-cc1d-50d6-bea5-720f6d22e335","slug":"definition","fullItemName":"Definition"},{"id":"d7f47150-a2c5-57f9-88aa-5353f86fc58a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e594be8-c4df-5032-ad75-87ab56cb2c7e","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7da5320-e6b9-59fc-8e5a-558ea4c298d9","slug":"complications","fullItemName":"Complications"}]},{"id":"e747d7e1-25ca-5f67-9d22-349d2b18eddd","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"ee9cab5c-4665-56a2-9005-028143cc8f59","slug":"suspecting-opioid-dependency","fullItemName":"Suspecting opioid dependency"},{"id":"20c15a53-634f-5cb4-a88a-7cb5115d810b","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"f37505e6-dc82-5755-b700-7d1966f8c252","slug":"management","fullItemName":"Management","subChapters":[{"id":"75fe82a9-9ba2-541a-80be-cd0cf879bca3","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"d05968e4-f2be-5378-b462-0b129f5dc5e6","slug":"management","fullItemName":"Scenario: Management"},{"id":"00d16467-be2b-538d-8a7c-4d4045cabd6e","slug":"managing-special-circumstances","fullItemName":"Scenario: Managing special circumstances"}]},{"id":"0cf2cc09-9ca4-58a8-91c7-d64c38924b5a","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"ccbe88d0-314a-57fa-a61a-8a83bbfc9baf","slug":"writing-prescriptions-for-substitution-therapy","fullItemName":"Writing prescriptions for substitution therapy"},{"id":"5c859eeb-d8fd-50f5-8b18-e1a6a71ac111","slug":"methadone","fullItemName":"Methadone"},{"id":"3021db45-0a93-5ca8-a386-8d3e71abad63","slug":"buprenorphine","fullItemName":"Buprenorphine"}]},{"id":"9547692f-53b7-5f09-944d-6a4a6229dead","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"0eafd778-db7f-578e-905f-1365ee1290a1","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"1d80b232-8932-503b-8765-30b929f15180","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"796c8942-47b7-56b5-a88a-cc0f133f5f3e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfb530c5-aa05-5f4c-9e26-43caae839601","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"955b9fba-573b-57a0-b099-cf3356d6e837","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f05fac2-c160-5e48-b55d-3898cce03ec0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0ead7d6b-f923-5852-bb7c-50aa97b9b2ff","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"ef534296-f504-5d3e-9b47-3c0f08322658"}},"staticQueryHashes":["3666801979"]}